Katherine Fogertey. "In recent years, October volatility has been even higher and even more of a standout." Bristol - Myers Squibb (NYSE: BMY ), Dish Network (NASDAQ: DISH ), Intel (NASDAQ: INTC ), Ford (NYSE: F ), J.C. Penney (NYSE
Bristol - Myers Squibb (NYSE: BMY ) declares $0.36/share quarterly dividend , in line with previous. Forward yield 2.82% Payable Nov. 3; for shareholders of record Oct. 3; ex-div Oct. 1. Post your comment!
side effect profile that rivals medications like Bristol - Myers Squibb 's (NYSE: BMY ) anti-blood clot drug Plavix which has caused ..... infection of the penis. Farxiga, a product of Bristol -Meyers Squibb and Complete Story »
2021, and hepatitis C regimens from Bristol and AbbVie could spark price wars if ..... initiatives. Martin, who was previously Bristol - Myers ' director of antiviral chemistry and ..... sees strong competition from firms like Bristol and AbbVie, or if pharmacy benefit managers
Novartis' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's Avastin and Eli Lilly and Bristol - Myers Squibb 's Erbitux. If Kyprolis fails in head-to-head studies against leading proteasome inhibitor Velcade, Amgen
By SA Transcripts : Bristol - Myers Squibb Company (NYSE: BMY ) Morgan Stanley Healthcare ..... the next session here with Bristol - Myers . Please note that we need ..... Chief Operating Officer for Bristol . He originally joined the
Sept 5 (Reuters) - Bristol - Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.
Teva Pharmaceutical Industries ( TEVA -0.2% ) launches its generic equivalent to Bristol - Myers Squibb 's ( BMY +0.2% ) Baraclude ( entecavir ) Tablets, 0.5 mg and 1 mg, in the U.S. Teva was first to file its ANDA so it has 180
believe a large portion of Bristol 's current valuation ..... clinical data are poor. Bristol carries a high price ..... upcoming patent losses. Bristol 's growth prospects ..... reinvestment in the business. Bristol - Myers Squibb discovers, develops
to its rheumatoid arthritis drug candidate clazakizumab and its migraine prevention candidate ADL403 from Bristol - Myers Squibb (NYSE: BMY ) due to its focus on other therapeutic areas. Clazakizumab is an IL-6 inhibitor which plays a key role